TY  - JOUR

T1  - Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis : results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE)

JO  - American Journal of Clinical Dermatology

PY  - 2022/05/14

AU  - Blauvelt A

AU  - Guttman-Yassky E

AU  - Paller AS

AU  - Simpson EL

AU  - Cork MJ

AU  - Weisman J

AU  - Browning J

AU  - Soong W

AU  - Sun X

AU  - Chen Z

AU  - Kosloski MP et al

ED  - 

DO  - DOI: 10.1007/s40257-022-00683-2

PB  - Springer Nature

VL  - 23

IS  - 3

SP  - 365

EP  - 383

Y2  - 2024/12/22

ER  -